Lesson plan

ethylphenidate

Ethylphenidate (EPH) is a central nervous system (CNS) stimulant and the ethyl analog of methylphenidate. Ethylphenidate acts as a norepinephrine–dopamine reuptake inhibitor, meaning it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters in the brain, by binding to, and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. Ethylphenidate, being almost identical to methylphenidate in both structure and pharmacodynamics, likely also doesn't solely act as a "classical" reuptake inhibitor but primarily as an inverse agonist at the dopamine transporter (DAT), inducing dopamine transporter reversal and subsequent dopamine release from the axon terminal into the synaptic cleft in a manner similar to but distinct from amphetamines. Ethylphenidate has appeared as a novel psychoactive substance (NPS) and has been reported in some regions as a recreational stimulant. It has been marketed through unregulated channels, where purity, dosage, and composition may vary. Its abuse potential is related to dopaminergic activity, particularly DAT interactions. Rapid delivery routes that produce higher concentrations in the brain may increase reinforcing effects and the likelihood of compulsive use.…

Back to article

Article summary

Ethylphenidate (EPH) is a central nervous system (CNS) stimulant and the ethyl analog of methylphenidate. Ethylphenidate acts as a norepinephrine–dopamine reuptake inhibitor, meaning it effectively boosts the levels of the norepinephrine and dopamine neurotransmitters in the brain, by binding to, and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. Ethylphenidate, being almost identical to methylphenidate in both structure and pharmacodynamics, likely also doesn't solely act as a "classical" reuptake inhibitor but primarily as an inverse agonist at the dopamine transporter (DAT), inducing dopamine transporter reversal and subsequent dopamine release from the axon terminal into the synaptic cleft in a manner similar to but distinct from amphetamines. Ethylphenidate has appeared as a novel psychoactive substance (NPS) and has been reported in some regions as a recreational stimulant. It has been marketed through unregulated channels, where purity, dosage, and composition may vary. Its abuse potential is related to dopaminergic activity, particularly DAT interactions. Rapid delivery routes that produce higher concentrations in the brain may increase reinforcing effects and the likelihood of compulsive use.…

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.